For years, many of us in the pain community have been told to choose between a short-acting over-the-counter pill and something more complicated.
Sometimes the only other option presented is a traditional opioid. That is not a real choice when you are trying to recover from surgery, get through a procedure, or manage moderate-to-severe acute pain without adding a new set of fears.
This week at PAINWeek 2026 in Las Vegas, Adneuris Therapeutics, a wholly owned subsidiary of Tris Pharma, presented new data on cebranopadol, its lead investigational therapy for moderate-to-severe acute pain. The company shared Phase 3 results from two surgical pain studies and a comprehensive abuse-potential assessment. Adneuris says these findings support a planned New Drug Application later this year.
markets.businessinsider.com
I pay attention when a medicine is studied this hard and designed around a different mechanism. Too often we hear about “safer opioids” without the data to back the claim. This program is trying to show both pain relief and a lower abuse signal.
Cebranopadol is not approved. It is investigational. That distinction matters. Still, the data presented today are the kind the pain community should understand now, not after a label already exists.
What the studies actually showed
The two pivotal Phase 3 studies are called ALLEVIATE-1 and ALLEVIATE-2. One used abdominoplasty, a soft-tissue surgical pain model. The other used bunionectomy, a hard-tissue surgical pain model. Testing across both settings is a high bar for an acute-pain medicine.
In ALLEVIATE-1, cebranopadol 400 µg produced a significant reduction in pain intensity from 4–48 hours compared with placebo (LS mean difference −59.2; p<0.001).
In ALLEVIATE-2, cebranopadol 400 µg produced a significant reduction in pain intensity from 2–48 hours compared with placebo (LS mean difference −56.1; p<0.001). Oxycodone also reduced pain versus placebo (LS mean difference −29.1; p=0.031).
Across both studies, rescue medication use was significantly lower with cebranopadol than with placebo (p<0.001). The company reported that cebranopadol was well tolerated, with no drug-related serious adverse events in these presentations.
markets.businessinsider.com
That last point matters. It does not mean nobody will ever need an opioid rescue. Some patients still do, and access for people who truly need that tool should never be taken away. It does mean that if a new mechanism can lower rescue use after surgery while reducing pain intensity, that is progress.
The new abuse-potential package is what further separates this story from many others. In recreational opioid users, cebranopadol at doses up to 2.5 times the anticipated maximum therapeutic dose showed lower abuse potential than Schedule II opioids hydromorphone and oxycodone and the Schedule IV opioid tramadol.
Cebranopadol was associated with a low incidence of euphoria-like events. Withdrawal-related adverse events after abrupt discontinuation were rarely reported and were not more common than placebo in studies of up to 14 weeks.
Preclinical work showed a lower tendency to reinforce drug-seeking behavior than selective mu-opioid agonists, along with weak physical dependence potential. Drug-discrimination studies suggested that activity at the nociceptin/orphanin FQ peptide (NOP) receptor tempers mu-opioid peptide (MOP) agonist effects. The company believes that dual action is why the abuse signal looks different.
markets.businessinsider.com
James Hackworth, Ph.D., Cebranopadol Development Lead at Adneuris, said the challenge is familiar to anyone living with pain: effective relief too often comes packaged with concerns about dependence, addiction, and misuse. He described cebranopadol as a fundamentally different approach, designed to provide meaningful pain relief while potentially mitigating many of the risks associated with existing treatments.
How it is different from what is already in the cabinet
Most traditional opioid pain medicines act primarily on the MOP receptor. Cebranopadol is being developed as a first-in-class dual-NMR agonist. That means it is designed to target both the NOP receptor and the MOP receptor at the same time.
This is not an over-the-counter product. It is not approved for acute pain, chronic pain, or anything else. It is not a replacement for acetaminophen, NSAIDs, or every opioid. If approved, it would be a prescription option aimed at moderate-to-severe acute pain.
According to Adneuris, cebranopadol has been studied in more than 34 clinical trials and more than 2,400 participants, with prior positive work in acute pain, chronic pain, and diabetic neuropathic pain. The FDA granted Fast Track designation for chronic low back pain. The National Institute on Drug Abuse, part of the National Institutes of Health, also awarded Tris a five-year grant of up to $16.6 million to study cebranopadol’s potential in opioid use disorder and other substance use disorders. Those programs are separate from the acute-pain NDA path, but they show how widely this mechanism is being examined.
biospace.com
That “investigational” language is important. This is not a cure for CRPS, RSD, or other complex chronic conditions. It is a possible new tool for a specific kind of pain. In our world, tools matter.
You can read the company’s PAINWeek announcement here and the earlier meeting preview here.
What I want patients to do with this information
Do not start, stop, or switch a medicine because of a conference presentation. Cebranopadol is not available as an approved treatment. Ask your provider what options are appropriate for your acute pain, your surgical plan, and your medical history.
I have spent more than two decades learning that trying smarter beats trying harder. Part of trying smarter is knowing what is coming through the pipeline, what the studies actually measured, and what questions to take to your care team.
If this medicine is approved, the next questions will be the practical ones: who it is for, how it is scheduled, what the label says about risk, and whether patients can actually get it. Until then, the job is to stay informed without treating press-release data as a prescription.
Learn more at adneuris.com and trispharma.com.
More options. Better data.
A dual-mechanism candidate studied in real post-surgical pain, with an abuse-potential package that looks different from oxycodone and tramadol. That is the kind of news the pain community should hear, and then discuss with the people who know our individual medical histories.
Never give up, and never give in. Keep asking for proper and timely care.
About the Author: Barby Ingle lives with reflex sympathetic dystrophy (RSD), migralepsy, endometriosis, and other chronic conditions. She is a chronic pain educator, patient advocate, motivational speaker, and best-selling author on pain topics.
More information is available at barbyingle.com.
Published by: International Pain Foundation, iPain Blog
